Abbott Laboratories (ABT) Reports Q3 Results and Plans Nutrition

Abbott Laboratories (ABT) reported Q3 adjusted EPS of $1.42, with revenue up 14.5% YoY to $13.01B. Q4 EPS guidance met expectations, but full-year 2026 sales growth forecast was lowered to ~6%. The company plans to spin off its Nutrition business by the end of 2027, aiming to focus on higher-growth healthcare sectors. Medical Devices and Diagnostics saw strong growth, while Diabetes Care faced reimbursement challenges.

Original reporting
Published Oct 21, 2026, 5:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 5:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ABT
Bearish
high confidence
Mentioned
$ABT
Relevance
8/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$ABTBearishHigh
01

Why it matters

The earnings release shows solid segment performance but a weaker outlook, prompting a likely sell‑off. The announced Nutrition spin‑off adds strategic complexity and could create a new investment opportunity.

02

Market read

First‑time reporting of Q3 results, guidance cut, and spin‑off plan makes this a high‑impact earnings news item for traders.

03

What to watch

Abbott's strong Diagnostics growth and recent Exact Sciences acquisition may provide upside that the article downplays.

Relevance 8/10Novelty 8/10Timing: after‑hours today

Background

Abbott Laboratories is a diversified health‑care company with segments in Medical Devices, Diagnostics, Established Pharmaceuticals, and Nutrition.

Company-level read

Ticker impact

$ABTBearishHigh confidence
Context

Abbott reported Q3 earnings with adjusted EPS $1.42 and cut full-year comparable sales growth outlook, while announcing a spin‑off of its Nutrition business.

Expected impact

downward pressure as investors price in lower sales growth and uncertainty around the Nutrition separation.

Evidence & confidence

Guidance cut and a major restructuring are material catalysts for a large‑cap health‑care stock.

Market effects

The cut in sales growth may pressure other diversified health‑care peers, while the Nutrition spin‑off could create a new pure‑play nutrition company.

U.S. health‑care sector may see modest downside as investors reassess growth assumptions.

Limited; primarily affects U.S. and global health‑care investors tracking Abbott.

Counterpoint

The spin‑off could unlock value if the Nutrition unit operates as a focused consumer‑health business, potentially offsetting short‑term earnings concerns.

Key entities

  • Abbott Laboratories

    U.S.-listed health‑care conglomerate (ticker ABT).

Related articles

$PHGMed

New Study Shows How Hybrid Imaging Can Guide Coronary Treatment Decisions

Conavi Medical (TSXV: CNVI, OTCQB: CNVIF) received FDA 510(k) clearance for its hybrid imaging system, combining IVUS and OCT. The company reported first U.S. commercial placement, early clinical benefits, and extended credit facilities. Peer-reviewed research supports hybrid imaging for coronary treatment decisions. Conavi aims to expand physician adoption and hospital placements.

$ABTMed

Here's How Abbott's EP Business Is Shaping Up for the Rest of 2026

Abbott's (ABT) Medical Devices segment saw 8% sales growth in Q3 2026, driven by Electrophysiology (EP) products. EP sales grew mid-to-high-teens globally and over 20% in the U.S. Volt PFA catheter adoption accelerated post-U.S. launch. Abbott received FDA approval for TactiFlex Duo and CE Mark for Amulet 360. Japan launch expected in Q4. LAA market weakness is a headwind. Thermo Fisher (TMO) and Insulet (PODD) also reported Q3 earnings.

$ABTMed

Can UltiSynq Lead Boost Abbott's Cardiac Rhythm Management Business?

Abbott's UltiSynq defibrillation lead received FDA and CE Mark approvals, backed by successful trial results. The device aims to improve cardiac rhythm management, with 98.5% successful implantation and 97.5% complication-free rate at three months. Abbott also received FDA's breakthrough device designation. Medtronic and Boston Scientific provided updates on their cardiac devices. Abbott shares have declined 12.2% over the past year, trading at a forward P/S of 3.60X.

$ABTMedAI 9/10

Abbott Touts Favorable Outcomes In Cardiovascular Device Trials

Abbott Laboratories (ABT) presented positive clinical trial results for two cardiovascular devices at a conference. The Amulet 360 LAA Occluder showed 96.3% complete closure in patients, with low complication rates. The SonicForce System achieved 97% procedural success in treating calcified coronary arteries. ABT shares rose 2.55% to $108.91.